
Immix Biopharma, Inc.: updates and filings
Price
$6.96
November 20, 2026Market cap $583M
What Ploutos Investor adds for Immix Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
September 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 30, 2026Other material eventsForm8-K
- Sep 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 20, 2026Other material eventsForm8-K
- Jun 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 29, 2026Shareholder voteForm8-K
- May 21, 2026Other material eventsForm8-K
- May 21, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 6, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 6, 2026Additional annual meeting materialFormDEFA14A
- Apr 6, 2026Annual meeting proxy statementFormDEF 14A
- Mar 30, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 27, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
- Mar 25, 2026Shares registered for employeesFormS-8
- Mar 25, 2026Material agreement enteredForm8-K
- Mar 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 20, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 30, 2026 | 8-K | Other material events | Document |
| Sep 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 20, 2026 | 8-K | Other material events | Document |
| Jun 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 29, 2026 | 8-K | Shareholder vote | Document |
| May 21, 2026 | 8-K | Other material events | Document |
| May 21, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 6, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 6, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 6, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 30, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 27, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
| Mar 25, 2026 | S-8 | Shares registered for employees | Document |
| Mar 25, 2026 | 8-K | Material agreement entered | Document |
| Mar 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 20, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 20, 2021.
The full analysis
What do Immix Biopharma's filings show?
The filings are where every one of Immix Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.